599 results on '"Weng, Wen-Kai"'
Search Results
2. Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report.
3. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
4. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
5. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma
6. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD
7. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
8. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents
9. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma
10. Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol
11. Clinical and Neuroradiological Features of Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma (MCL) (S23.007)
12. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
13. Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era
14. Management of post‐autologous transplant relapse in patients with T‐cell lymphomas.
15. Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
16. Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma
17. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
18. Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T‐cell lymphomas
19. CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
20. CD19 Antigen Density Down-Regulation at Time of Progression in Large B-Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel
21. Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
22. Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma
23. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia
24. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
25. Pembrolizumab in mycosis fungoides with PD-L1 structural variants
26. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
27. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
28. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma
29. 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
30. Enhancing Wave Energy Harvesting with a Submerged Crescent-Shaped Plate
31. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort
32. Tabelecleucel for EBV+PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
33. Experimental Study on the Generation and Attenuation of Landslide Tsunamis
34. Validation of the Hematopoietic Cell Transplantation–Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
35. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era
36. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
37. Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
38. Research on motion characteristics of floating breakwater with pneumatic chamber
39. Laboratory experiments and numerical modeling of wave transformations on a complex reef platform
40. Immune Phenotypic Quantification of Axicabtagene Ciloleucel and Brexucabtagene Autoleucel Demonstrates Lymphoma Histology Specific Differences in CAR19 Expansion and Toxicity
41. Outcomes of Hematopoietic Cell Transplantation for Hepatosplenic T-Cell Lymphoma: A US Multicenter Collaborative Study
42. CD22 CAR T Cell Therapy Induces Durable Remissions in Patients with Large B Cell Lymphoma Who Relapse after CD19 CAR T Cell Therapy
43. Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL
44. Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
45. Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation
46. A Study of Long Wave Attenuation over Composite Undulating Breakwaters
47. The performance characteristics of inclined highly pervious pipe breakwaters
48. Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
49. Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
50. The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.